Region Skane

At Region Skane the focus is on improving diagnostic tools, such as PET imaging for neurodegeneration and rapid HPV testing, aiming to enhance early detection and patient management.

• Tau PET imaging for Alzheimer’s disease
• Integrated HPV screening in cervical program
• Diagnostic accuracy of iron deficiency tests

The department collaborates with local primary care to translate these technologies into routine clinical practice.

Researchers are evaluating novel combination therapies for mantle cell lymphoma, seeking to extend progression‑free survival and offer less toxic alternatives.

• Rituximab/Ibrutinib versus chemotherapy
• Biomarker studies in lymphoma
• Patient‑reported outcomes in blood cancers

The trial team includes seven investigators, reflecting a strong multidisciplinary effort.

The site conducts studies on cervical cancer prevention through coordinated HPV vaccination and screening, targeting a rapid reduction of infection rates nationwide.

• Population‑level HPV vaccination impact
• Screening program effectiveness
• Long‑term cancer incidence monitoring

Findings will guide public‑health policies across Sweden.

A randomized trial investigates whether a short course of antibiotics can shorten symptom duration in severe group A streptococcal‑negative tonsillitis, informing primary‑care prescribing habits.

• Antibiotic versus no‑treatment for tonsillitis
• Centor score‑guided management
• Safety outcomes in acute throat infections

Results are expected to support evidence‑based guidelines for clinicians.

Studies address nutritional deficiencies, evaluating alternate‑day iron supplementation in adolescent girls to combat iron deficiency anemia and improve overall health.

• Feasibility of alternate‑day iron dosing
• Diagnostic performance of iron biomarkers
• Adherence strategies for teens

The project integrates community outreach to ensure broad participation.

Ongoing exploratory work examines the safety and rapid‑acting antidepressant potential of ketamine‑derived compounds as adjuncts to standard therapy for major depressive disorder.

• One‑week ketamine adjunct trial
• Mood rating scale outcomes
• Side‑effect monitoring

This line of research may open new avenues for treatment‑resistant depression.

Clinical trials test the efficacy of pramipexole in reducing anhedonia among patients with major depression, aiming to enhance symptom relief beyond conventional antidepressants.

• Pramipexole for anhedonia
• Neurochemical target validation
• Quality‑of‑life assessments

Collaboration with psychiatric services ensures comprehensive patient care.